Apogee's Zumilokibart Delivers Strong 52-Week Phase 2 Data in Atopic Dermatitis, Showing Durable Efficacy with Quarterly/Biannual Dosing
APGE has more than doubled off its 52-week low of $26.2 on elevated volume (2.9× avg).
Summary
Apogee Therapeutics announced highly positive 52-week maintenance data from Part A of its Phase 2 APEX clinical trial for zumilokibart (APG777) in moderate-to-severe atopic dermatitis. The results demonstrated durable maintenance and deepening of responses, with 75-85% of patients maintaining EASI-75 and 78-86% maintaining vIGA 0/1 with every 3- and 6-month dosing. This data is a significant de-risking event for Apogee's lead candidate, highlighting its potential best-in-class profile due to significantly less frequent dosing compared to current treatments. This strong efficacy and convenient dosing schedule could be transformative for patients and provides a substantial competitive advantage. Investors will now focus on the upcoming APEX Part B 16-week induction readout in Q2 2026 and the planned initiation of Phase 3 trials in the second half of 2026.
At the time of this announcement, APGE was trading at $79.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6B. The 52-week trading range was $26.20 to $84.56. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.